AFT Pharmaceuticals’ shares fall as drug fails FDA threshold

AFT Pharmaceuticals’ shares fall as drug fails FDA threshold
AFT Pharmaceuticals managing director Hartley Atkinson still believes Pascomer shows promise. (Image: AFT Pharmaceuticals)
Riley Kennedy
AFT Pharmaceuticals’ shares have fallen this morning after the company said a drug it is developing to treat facial angiofibromas (FA) had failed to reach the threshold for US Food and Drug Administration (FDA) registration.The company’s shares declined 3.3% to $3.80 in morning trading, after the pharmaceutical company released the findings of its study of its orphan drug Pascomer, which it said found “statistically significant” benefits. However, it did not reach the threshold on the IGA scale – a five-point...

More Markets

Takeover bid is opportunistic and undervalued: THL
Markets

Takeover bid is opportunistic and undervalued: THL

Tourism Holdings' board remains open to engagement with the Consortium.

One man, five boards: The NZ director spiderweb
Markets

One man, five boards: The NZ director spiderweb

James Miller is at the top of the directorship pyramid.

Increased US tariffs drive NZ stocks lower
Markets Market Close

Increased US tariffs drive NZ stocks lower

F&P Healthcare and Ebos shares both dropped over 2% on the tariff news.

Jamie Gray 01 Aug 2025
Journee to succeed Withers as Warehouse chair
Retail

Journee to succeed Withers as Warehouse chair

Journee ensures "strong continuity of leadership", Joan Withers said.

Gregor Thompson 01 Aug 2025